TOLL FREE: 888.88.INFECT
PHONE: 517.536.8210
FAX: 517.536.8205

THE WELLHOFF CENTER
7190 S. BROOKLYN RD.
JACKSON, MI 49201

TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions

Soft Tissue Infection

Soft tissue infections affect the skin, subcutaneous tissue, fascia, and muscle. These infections develop when there is a break in the skin, such as a wound or injury, that allows a microbe to enter. A weakened immune system greatly increases the risk of developing this condition. Our soft tissue infection studies aim to determine the efficacy of novel therapeutics by assessing pathogen load and test subject survival.

Procedure
We have established a soft tissue infection model in mice in which animals receive a challenge with an infectious agent via intramuscular (IM) injection in one or both quadriceps muscles. Test article may be administered via oral gavage (PO) or subcutaneous (SC), intravenous (IV), or intraperitoneal (IP) injection. The route, duration, and frequency of dosing can be customized to meet client needs. Endpoints for this study include mortality tracking and CFU burden in harvested organs and/or blood. Pharmacokinetic profiling, blood chemistry, and histology are available upon request.

Pathogens
TransPharm has validated a thigh infection model using the following pathogens:

  • Acinetobacter baumannii
    • ATCC 17961
  • Enterococcus faecalis
    • EFS-007
  • Escherichia coli
    • ATCC BAA-457
    • ATCC 25922
  • Klebsiella pneumoniae
    • ATCC BAA-2146
  • Staphylococcus aureus
    • ATCC BAA-1717 (MRSA)
    • ATCC 29213
    • USA300 (MRSA)
  • Streptococcus pneumoniae
    • 02J1095
  • Streptococcus pyogenes
    • ATCC 19615
    • SPI-3541

Additional validations are available upon request.